Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
The affected drug is brecanavir, also known VX-385. GlaxoSmithKline told Vertex it would be too difficult to develop an appropriate formulation of brecanavir. The drug was already in mid-stage clinical testing.
The collaboration, started in 1993, has already yielded two other HIV treatments that are already on the market, Agenerase and Lexiva. The abandoning of brecanavir does not affect the current marketing agreement between Vertex and GlaxoSmithKline for the other two drugs.
